China Digest: Tencent backs Versa; Shanghai Cell Therapy secures $136m Series C

China Digest: Tencent backs Versa; Shanghai Cell Therapy secures $136m Series C

Artist impression of an immune system T-cell.

Tencent Holdings has led a series A round in Chinese AI-powered app developer Versa while Legend Capital-backed Shanghai Cell Therapy has completed a $136-million series C round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter